article thumbnail

Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023

Health Law Advisor

To advance these efforts, CMS established a Medicare Drug Rebate and Negotiations Group dedicated to the IRA and set forth the agency’s intended overarching timeline to implement the various IRA provisions, such as the Medicare Drug Price Negotiation Program and the Part D redesign.

article thumbnail

Democrats Didn’t Achieve All Their Goals, but Inflation Reduction Act Makes Historic Medicare Changes

Kaiser Health News

First, it would give the federal government the ability to negotiate prices of some drugs purchased by Medicare beneficiaries, a tool that has long been opposed by the drug industry. Never before have we been able to negotiate prescription drug prices. Those prices would take effect in 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries. Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D. New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges. Am J Prev Cardiol. 2022 Aug 2;11:100370. Lancet Oncol.

article thumbnail

A Health Consumer Bill of Rights: Assuring Affordability, Access, Autonomy, and Equity

Jane Sarashon

In addition to highlighting the Patient’s Bill of Rights, NABIP’s keynotes and general sessions will speak to similar topics being brainstormed at VIVE this week — including mental health, maternal health, pharmacy and prescription drugs (pricing, PBMs), population health, and Medicare and Medicaid innovations.

ACA 113
article thumbnail

Magnolia Regional used price transparency IT to get more CHF patients to fill their prescriptions

Healthcare It News

"With prescription drug prices rising at every turn, patients need price transparency and the ability to discuss options with their doctors during office visits," Davis advised. ADVICE FOR OTHERS.

article thumbnail

Supreme Court Clarifies that Subjective (Not Objective) Knowledge of Falsity of Claim Dictates False Claims Act Liability

Healthcare Law Blog

In the underlying Seventh Circuit cases, relators alleged that retail pharmacies had knowingly submitted false reports of their Usual and Customary (“U&C”) drug prices to the government for reimbursement under Medicare Part D and Medicaid, because the reports allegedly did not account for discounted drug prices offered through certain prescription (..)

article thumbnail

More Federal Action in the Pharmaceutical Sector as PBM Bill Advances in the Senate

Health Law Advisor

1339) reflects the overarching legislative push by members from both sides of the aisle and chambers of Congress to address drug pricing issues through federal fixes to the PBM framework. Unlike the IRA, which targeted the Medicare program, the provisions of S. 1339, adding several new amendments to create the version of S.